Skip to main content
Thymosin Alpha-1 Research

New-cell output, depleted immunity and the unfinished work of recovery.

Thymosin Alpha-1 references

The full source list follows, including early immune-reconstitution work, mechanistic experiments and trials with disappointing outcomes.

HIV and immune reconstitution

For the central Thymosin Alpha-1 question, start with the HIV pilot measuring thymic output and CD4 counts. The 1994 combination study gives an earlier clinical context; the 2024 immunological-nonresponder study returns to immune recovery during antiretroviral treatment.

The stem-cell transplant cohort and haemodialysis vaccine pilot extend the question into different kinds of immune impairment.

Mechanisms and illness outcomes

The original sequence analysis identifies the peptide. The IDO and dendritic-cell experiments examined mechanisms in mouse and human dendritic cells and mice, while the SARS-CoV-2 blood-cell model used human blood cells outside the body.

The ETASS sepsis trial and TESTS phase 3 trial are best read together. For hepatitis, the lamivudine meta-analysis sits alongside a Cochrane review protocol whose background discusses earlier studies. That protocol should not be mistaken for a completed systematic review.

Safety and other clinical settings

The comprehensive literature review and later safety review cover tolerability. The autoimmune serum study concerns endogenous levels. The severe COVID-19 cohort is retrospective, and the cancer reappraisal draws on preclinical and clinical combination research.

The HIV pilot still nags at me because its two measurements refuse to settle into a simple success story. The full bibliographic entries below make it possible to follow the argument back to the papers.

  1. Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A. 1977;74(2):725-729. ↗
  2. Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8. ↗
  3. Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583. ↗
  4. Dominari A, Hathaway III D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67-78. ↗
  5. Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265-2274. ↗
  6. Liu Y, Pan Y, Hu Z, et al. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis. 2020;71(16):2150-2157. ↗
  7. Costantini C, Bellet MM, Pariano M, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019;9:873. ↗
  8. Garaci E, Perno CF, et al. A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy. Clin Infect Dis. 2004;38 Suppl 2:S141-S143. ↗
  9. Perruccio K, Bonifazi P, Topini F, et al. Thymosin alpha1 to harness immunity to pathogens after haploidentical hematopoietic transplantation. Ann N Y Acad Sci. 2010;1194:153-161. ↗
  10. Garaci E, Rocchi G, Perroni L, et al. Combination treatment with zidovudine, thymosin alpha 1 and interferon-alpha in human immunodeficiency virus infection. Int J Clin Lab Res. 1994;24(1):23-28. ↗
  11. Carraro G, Naso A, Montomoli E, et al. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. Vaccine. 2012;30(6):1170-1180. ↗
  12. Yang YF, Zhao W, Zhong YD, et al. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J. 2009;6:63. ↗
  13. Htet NH, Naing C, Vongpunsawad S, Win TT, Poovorawan Y. Thymosin-alpha-1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2022;(3):CD014610. ↗
  14. Ricci D, Etna MP, Severa M, et al. Novel evidence of Thymosin α1 immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model. Int Immunopharmacol. 2023;117:109996. ↗
  15. Chen C, Wang J, Xun J, et al. Role of thymosin alpha1 in restoring immune response in immunological nonresponders living with HIV. BMC Infect Dis. 2024;24(1):78. ↗
  16. Pica F, Chimenti MS, Gaziano R, et al. Serum thymosin α1 levels in patients with chronic inflammatory autoimmune diseases. Clin Exp Immunol. 2016;186(1):39-45. ↗
  17. Dinetz E, Lee R. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. Altern Ther Health Med. 2024;30(1):6-12. ↗